MATN1 and central nervous system cancer: In addition, the level of MATN1‐AS1 could serve as an independent prognostic biomarker for glioma patients, so as some clinical features such as KPS (P = .033) and WHO grade (P = .032), while others had no impact on the prognosis (Table 2).